9 results about "Vein occlusion" patented technology

Provided in the present invention is an atraumatic vein occlusion clip for organ transplantation, the clip comprising a fixed clip body portion, wherein a first clamping part is provided at the front end of the fixed clip body portion, the first clamping part is connected to the fixed clip body portion by means of a connecting part, and a clamping opening is provided opposite the connecting part; and a sliding groove is provided in the fixed clip body portion, limiting teeth are provided on two sides of the upper part of the sliding groove, an adjustment assembly is slidably provided in the sliding groove, the front end of the adjustment assembly is connected to a movable clip body portion, a second clamping part is provided at the front end of the movable clip body portion, and the second clamping part cooperates with the first clamping part to occlude a vein. The adjustment assembly is used to adjust the extension length of the movable clip body portion, so as to adjust the clamping distance between the first clamping part and the second clamping part, and the clamping force is fixed, such that a medical staff member can directly sense the degree of clamping during adjustment, and the atraumatic vein occlusion clip has a better vein occlusion effect, and is more convenient to use.

The invention belongs to the crossing field of traditional Chinese medicine modernization and biotechnology, and particularly relates to application of a metabolic marker in preparation of a product for auxiliary diagnosis of retinal vein occlusion (RVO) or evaluation of prognosis of treatment of RVO by ginseng-wolfberry omentum granules. The metabolic marker is selected from at least one of the following metabolites: leukotriene B4, (R)-2-feruloyl-1-(4-hydroxyphenyl)-1, 2-ethylene glycol, hyoscyamine base A6, 11, 12-epoxyeicosatrienoic acid, 3, 3 ', 4, 4'-tetrahydroxy-5, 6, 7, 8, 9, 10, 11, 12-epoxyeicosatrienoic acid, 3, 3 ', 4, 4'-tetrahydroxyl-5, 6, 7, 8, 10-tetrahydroxyl-5, 7, 8, 10 The invention relates to an anti-inflammatory agent which is prepared from 5, 5 '-diisopropyl-2, 2'-dimethyl biphenyl (3, 3 ', 4, 4', 1-ethyl piperidine, flavin mononucleotide, crystal orchid glycoside, 2-O-caffeoyl arbutin, dimethyl ellagic acid glucuronide, 4 '-hydroxy-3, 4, 5-resveratrol trimethyl ether, 3'-methoxy petamicin, phenylalanyl-leucyl-isoleucyl-tyrosine and dihydroferulic acid-4-sulfate.

To provide treatment of AMD using an AAV2 variant with aflibercept.SOLUTION: The present disclosure provides pharmaceutical compositions and methods thereof for treatment of age-related macular degeneration (AMD) in a subject by administering intravitreally a pharmaceutical composition adapted for gene therapy, comprising a vector having a nucleic acid sequence that encodes aflibercept. The present disclosure relates to pharmaceutical compositions and methods for prevention or treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR) in patients with DME, retinal vein occlusion, and related eye diseases or conditions, in a primate or human subject by administering intravitreally or subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector or viral particles (e.g., rAAV) comprising a nucleic acid encoding aflibercept or a functional fragment or variant thereof.SELECTED DRAWING: None

The present invention relates to novel methods, uses and compositions of annexin A5 protein as combination therapy with one or more anti-VEGF agents, the present invention relates to compounds, for example, for the prevention or treatment of macular edema, retinal vein occlusion and / or one or more diseases, conditions or conditions associated with and / or caused by macular edema or retinal vein occlusion, and / or other conditions suitable for treatment with anti-VEGF agents. In a preferred embodiment, the annexin A5 is administered systemically, such as intravenously.

The invention relates to the technical field of ophthalmic drugs, and particularly discloses application of polysulfonic acid mucopolysaccharide in preparation of drugs for treating ophthalmic diseases, and the ophthalmic diseases comprise xerophthalmia, corneal injury, retinal vein occlusion (RVO) or filtration bubble scarring after glaucoma filtration operation. Experiments prove that the polysulfonic mucopolysaccharide can prolong the tear film rupture time of a dry eye rabbit model, reduce the cornea fluorescein staining score, improve the optimal corrected vision of acute retinal vein occlusion patients, reduce the macular center thickness and inhibit the expression level of lipopolysaccharide-induced human corneal epithelial cell IL-6 and TNF-alpha inflammatory factors, and can be used for treating acute retinal vein occlusion. The migration and proliferation speed of the human corneal epithelial cells is improved.

The invention relates to application of a microglial cell TAK1 gene as a target spot in treatment of retinal neovascular diseases. The invention finds that by specifically knocking out the microglial cell TAK1 gene, the number of neovascular clusters under pathological conditions can be effectively reduced, migration and proliferation of retinal tissue neovascular endothelial cells are inhibited, pathological retinal neovascularization is effectively inhibited, but the physiological angiogenesis capability of human retinal microvascular endothelial cells is not influenced. Therefore, retina neovascular diseases including diabetic retinopathy, premature infant retinopathy, retinal vein occlusion, familial exudative vitreoretinopathy and the like can be effectively treated by specifically knocking out the microglial cell TAK1 gene. The invention provides a new target and a new idea for the treatment of retinal neovascular diseases.

The application relates to an analysis method, system and device of a fundus image. The method comprises the following steps: acquiring a fundus image; classifying the fundus image based on coarse-grained features to obtain a first classification result, wherein the first classification result comprises retinal vein obstruction, retinal artery obstruction and a normal sample; classifying the fundus image with the first classification result of retinal artery obstruction based on fine-grained features to obtain retinal branch artery obstruction and central retinal artery obstruction classification results, or classifying the fundus image with the first classification result of retinal vein obstruction based on fine-grained features to obtain retinal branch vein obstruction and central retinal vein obstruction classification results. The application aims to realize classification and prediction of retinal vascular obstruction by fusing coarse-grained features and fine-grained features through a constructed fundus image hierarchical model, and to explore the capability and potential application value of the fundus image analysis.

The invention provides a construction method of a retinal vein occlusion animal model, and belongs to the technical field of medicines. The method comprises the following steps of: performing eyeball surface anesthesia on an anesthetized non-human primate animal, puncturing an eyeball after disinfection to establish two sclera tunnels, respectively inserting an illumination optical fiber and an intraocular laser optical fiber into the two sclera tunnels, then injecting a photosensitizer through limb vein, immediately performing laser photocoagulation on the retinal vein under illumination of the illumination optical fiber after injection, and performing laser photocoagulation on the retinal vein under the illumination of the illumination optical fiber. And obtaining the retinal vein occlusion animal model. According to the method, the retinal vein occlusion model can be successfully constructed, secondary macular edema and vascular recanalization are carried out for a long time and can be maintained for 4-5 weeks, the manifestation sign of retinal hemorrhage after retinal vein occlusion is close to that of human beings, and the method has clinical drug responsiveness, shows the clinical research value and has good application prospects. And a good research model is provided for research in the aspects of etiology, pathology and therapeutics.